If your insurance won’t cover a weight loss medication like Wegovy or Zepbound, you have more routes than the denial letter admits: appeal the decision through your plan’s internal and external review, use the manufacturer’s savings card or lower-cost vial program, and pay with pre-tax HSA or FSA dollars when the prescription treats a diagnosed condition. Which route fits depends on why the plan said no.
Figure Out Why You Were Denied
Denials for GLP-1 weight loss drugs almost always come down to one of three reasons, and your next step depends on which one applies.
The first is formulary placement. Every plan maintains a list of covered drugs organized into cost tiers, and many insurers either leave Wegovy and Zepbound off entirely or place them on the highest tier. Some plans cover these medications only when prescribed for a different condition, such as Type 2 diabetes or cardiovascular risk reduction. Formularies also change year to year.1eCFR. 45 CFR 156.122 – Prescription Drug Benefits
The second is medical necessity. Even on-formulary drugs usually require prior authorization. Standard criteria include a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition like high blood pressure, Type 2 diabetes, high cholesterol, or sleep apnea. Your doctor typically has to document failed attempts at diet and exercise, and some plans demand participation in a structured weight management program for three to six months before they’ll consider approval. A lot of denials at this stage come from thin paperwork rather than an ineligible patient.
The third is a blanket exclusion. Some policies categorically refuse to cover “medications for the treatment of obesity or weight control,” which is common in employer-sponsored plans. Others impose annual caps that function like exclusions in practice. A $1,500 annual cap on obesity drugs barely covers a single month of Wegovy at its roughly $1,350 list price.
Pull your denial letter and your Summary of Benefits. If the reason is a formulary or documentation issue, you can appeal with a strong chance of success. If it’s a blanket exclusion written into the policy, appeals rarely overturn it, and your energy is better spent on the cost-reduction routes below.
Appeal the Denial
Federal law requires most health plans to offer a two-stage appeal: an internal appeal handled by the insurer, then an external review by an independent third party.2eCFR. 45 CFR 147.136 – Internal Claims and Appeals and External Review Processes
The Internal Appeal
Your denial letter or Explanation of Benefits should state the reason, the documents you can submit, and your deadline. Read it carefully. If the denial was based on a paperwork gap, resubmitting with the missing information often resolves it without a formal fight.
For medical-necessity denials, build the strongest file you can. A detailed letter from your prescribing physician explaining why the medication is clinically appropriate carries real weight. Add medical records showing prior treatments that didn’t work, relevant lab results, and clinical guidelines supporting GLP-1 use for your condition. The deadline for post-service claims is typically 180 days.
The External Review
If the internal appeal fails, request an external review. You have four months from the date you receive the final internal denial to file.3eCFR. 26 CFR 54.9815-2719 – Internal Claims and Appeals and External Review Processes If that date falls on a weekend or federal holiday, the deadline rolls to the next business day. External reviewers aren’t bound by your insurer’s internal policies, so denials based on thin reasoning sometimes get overturned here. If the reviewer rules in your favor, the insurer must comply.
Use Manufacturer Savings Programs
If appeals aren’t available or don’t work, manufacturer programs can take a serious bite out of your monthly bill. Terms change frequently, so verify before you rely on them.
Wegovy
Novo Nordisk’s savings card can bring Wegovy down to as little as $25 per month if you have commercial insurance, with maximum savings of $100 per month.4NovoCare. Savings Offer Program for Patients Taking Wegovy You must be at least 18, a U.S. resident, and enrolled in a commercial plan. Medicare, Medicaid, TRICARE, and VA beneficiaries are not eligible. People covered by Federal Employees Health Benefits, ACA marketplace plans, and state employee plans do qualify.
Wegovy’s list price is around $1,350 per month. Novo Nordisk has announced that effective January 1, 2027, it will cut the list price to $675 per month across all doses, which should lower out-of-pocket costs for patients whose copays are tied to list price.
Zepbound
Eli Lilly runs a tiered program. If your commercial plan covers Zepbound, the savings card can drop your copay to $25 per month, with maximum savings of $100 per month and a $1,300 annual cap.5Zepbound. Savings Options for Zepbound If your commercial plan doesn’t cover it, you can still use the card to pay $499 per month for single-dose pens.
Lilly also sells Zepbound in single-dose vials through LillyDirect at lower prices than the pens. Under the Self Pay Journey Program, the 2.5 mg starting dose is $299 per month, 5 mg is $399, and all higher doses are $449 per month, provided you refill within 45 days of your previous delivery.6Eli Lilly. Lilly Lowers the Price of Zepbound Tirzepatide Single-Dose Vials The vials require you to draw and inject the medication yourself rather than using a pre-filled pen. The monthly list price for pens is $1,086, so the savings are substantial.
Pay With HSA or FSA Dollars
Health Savings Account and Flexible Spending Account funds can cover weight loss medication, but only under specific conditions. The drug must be prescribed by a physician to treat a diagnosed medical condition such as obesity, diabetes, or hypertension.7Internal Revenue Service. Publication 502 – Medical and Dental Expenses General weight management without an underlying diagnosis won’t qualify.
Most FSA administrators require a letter of medical necessity from your doctor before reimbursing weight loss expenses. With an HSA, hold onto that letter and your pharmacy receipts in case the IRS audits your account. For 2026, the HSA contribution limit is $4,400 for individual coverage and $8,750 for family coverage, and the health FSA contribution limit is $3,400.8Internal Revenue Service. IRS Notice – 2026 HSA Contribution Limits Those won’t cover a full year of most GLP-1 medications at list price, but they shrink the after-tax cost of whatever you spend.
Deduct Qualifying Costs on Your Taxes
If you pay out of pocket and the drug is prescribed to treat a specific diagnosed disease, those costs count as deductible medical expenses on your federal return. The IRS draws a clear line: weight loss treatment qualifies only when it addresses a diagnosed condition such as obesity, hypertension, or heart disease, not when the goal is general weight management.7Internal Revenue Service. Publication 502 – Medical and Dental Expenses
You can only deduct medical expenses above 7.5% of your adjusted gross income, and you have to itemize on Schedule A rather than taking the standard deduction. A year of GLP-1 medication at over $1,000 per month can push you past that threshold, especially combined with other medical costs. Keep every pharmacy receipt and documentation of your diagnosis.
If You’re on Medicare
Standard Medicare Part D has not covered medications prescribed primarily for weight loss, so most Medicare beneficiaries have had no coverage path for Wegovy or Zepbound when prescribed for obesity alone.
CMS has launched the Medicare GLP-1 Bridge, a demonstration program that operates outside standard Part D and covers eligible GLP-1 medications, including Wegovy and Zepbound, when used specifically for weight reduction.9Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge Because it doesn’t run through your Part D plan, the process to access it is different from normal prescription benefits.
Part D does cover GLP-1 medications when prescribed for other FDA-approved uses, such as Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, or Wegovy to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.9Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge If your doctor documents one of these indications, standard Part D coverage may apply through your plan’s formulary exception process.
Be Careful With Compounded Versions
Compounded semaglutide and tirzepatide are sold at much lower prices than the brand-name drugs, but they are not the same products. Compounded drugs skip the FDA’s review for safety, effectiveness, and quality, and the FDA has issued specific warnings about them.10U.S. Food and Drug Administration. FDA Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Documented concerns include dosing errors that led to hospitalizations, fraudulent labeling where the pharmacy named on the product didn’t make it, products shipped without proper refrigeration, and the use of different salt forms (such as semaglutide sodium or semaglutide acetate) that are chemically different from the approved drug. As of July 2025, the FDA had received over 1,100 adverse event reports across compounded semaglutide and tirzepatide, and the agency believes those numbers are underreported because most compounding pharmacies aren’t required to submit adverse event data.10U.S. Food and Drug Administration. FDA Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Federal law generally prohibits pharmacies from compounding drugs that are essentially copies of commercially available FDA-approved products. Compounding was permitted while semaglutide and tirzepatide sat on the FDA’s drug shortage list, but both shortages have since been resolved. The FDA has ended its enforcement discretion periods, so compounders producing these drugs now face potential regulatory action.11U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins To Stabilize Compounded versions won’t disappear overnight because ongoing litigation is challenging the FDA’s authority, but the legal ground is unstable. If you’re relying on a compounded product, have a backup plan.
When Appeals and Alternatives Aren’t Enough
If the standard appeal path and cost-reduction routes have run out, there are a few further options worth knowing about.
Filing a complaint with your state’s department of insurance is free. Every state has a regulator that investigates consumer complaints, and the National Association of Insurance Commissioners maintains a directory.12National Association of Insurance Commissioners. Consumer Resources A complaint is worth filing if you believe the insurer misapplied its own policy terms, applied exclusions inconsistently, or engaged in misleading practices. It won’t always change the outcome, but it creates a paper trail and sometimes moves cases stuck in the appeals process.
If your coverage comes through an employer, your plan is likely governed by the Employee Retirement Income Security Act. ERISA lets you sue in federal court after exhausting your plan’s internal review process, with the right to recover benefits due under the plan’s terms.13Office of the Law Revision Counsel. 29 USC 1132 – Civil Enforcement Courts can award the cost of denied benefits and, at their discretion, reasonable attorney’s fees. Punitive damages and emotional distress claims are not available. For a drug costing more than $1,000 per month, an ERISA case can still be worth pursuing, but it’s not a fast remedy.